Sunifiram (DM-235) is a piperazine derived research chemical which has nootropic effects in animal studies with significantly higher potency than piracetam. A number of related compounds are known, including unifiram (DM-232).
Sunifiram, also known as 1-benzoyl-4-propanoylpiperazine is a nootropic that was only first researched in the year 2000. It has a similar chemical structure to Piracetam but initial studies show that it is significantly more potent than this widely used racetam. Sunifiram so far shows very positive results as memory enhancer and it is currently being investigated for potential treatment of Alzheimer’s and other diseases related to cognitive decline.
Sunifiram (DM-235) is an AMPAkine drug (acting via AMPA receptors) that exerts anti-amnesiac properties. With similar actions as Nefiracetam, it holds promise as a cognitive enhancer but is relatively understudied currently.
Formal Name：PHENYLETHYL CAFFEATE;PHENETHYL 3,4-DIHYDROXYCINNAMATE;PHENETHYL CAFFEATE
Molecular Weight: 246.30492 g/mol
Purity ≥99 %
CAS Number: 314728-85-3
Sunifiram is one of the newest nootropics on the market showing very promising initial results. It falls into the ampakine family of nootropic supplements because it is an AMPA agonist. Some reviews have suggested that it works similarly to Piracetam but it is over 1000 times more potent than Piracetam for the same dosage. Sunifiram is highly effective at boosting memory function as well as attention span, learning, decision making and alertness. A lot of initial reviews and user experiences suggest that Sunifiram could become one of the most popular nootropic study aids for improving
Structurally related to Piracetam, Sunifiram is a relatively new entrant in the field of Nootropics (first studies published in 2000) that has shown a considerably higher potency than Piracetam in the animal studies that have been conducted thus far. The early animal studies that have been conducted point to Sunifiram being an anti-amnesiac and general cognitive aid.
The recommended dose of Sunifiram is 7mg and it may be taken up to three times within a day. This cognitive enhancer is sold in capsules, powder, and tablet form.
1、Sunifiram activates AMPA-mediated neurotransmission.
2、It enhances LTP in a bell-shaped dose–response relationship. This enhancement by sunifiram is associated with an increase in phosphorylation of AMPAR through activation of protein kinase II (CaMKII) and an increase in phosphorylation of NMDAR through activation of protein kinase C α (PKCα). More specifically, sunifiram stimulates the glycine-binding site of NMDAR with concomitant PKCα activation through Src kinase. Enhancement of PKCα activity triggers hippocampal LTP through CaMKII activation.
3、Sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation. PKC activation may be a common mechanism amongst cognition stimulating drugs from different chemical classes.
4、Sunifiram aids in the release of acetylcholine in the cerebral cortex.
Sunifiram is considered to be a safe drug with few or no potential side effects of concern. However, there are some minor side effects that can be mentioned, including headaches, anxiety, insomnia or sleeplessness, and nausea. All of these side effects are treatable and are not consider a serious risk to anyone’s health (Nootriment Organization, 2014). Because of its marketing as a brain drug and its notable lack of side-effects, the present concern is that people will acquisition the drug illegally and use the drug without need and in higher doses than would normally be prescribed. Because the drug mimics the effects experienced when one takes amphetamine and methylphenidate, which aid in promoting wakefulness many students are using the drug to improve overall test scores. Unfortunately, studies have yet to show if there is an addictive quality present when taken freely (Mullen, 2014).
That said studies are still being done to determine the overall safety, efficiency and effectiveness of Sunifiram. However, all current studies and preliminary data are showing that there are few side effects and the treatment seem to be incredibly beneficial in the treatments of serious conditions, like amnesia, Alzheimer’s and Parkinson’s disease. Nootropics may not be the solution to boosting one’s brain power, especially without the advice and overseeing by a doctor, but its applications in aiding people with reestablishing, maintaining, and improving the memories of those who possess conditions that can strip their recall and be freed from some the mentally debilitating aspects of these illnesses or injuries is important. In the end, the further research into Sunifiram and all of the Nootropic drugs is worthwhile and potentially beneficial well into the future.